These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12534393)

  • 41. Recent status of the antisense oligonucleotide approaches in oncology.
    Ma L; Calvo F
    Fundam Clin Pharmacol; 1996; 10(2):97-115. PubMed ID: 8737953
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nanoparticles for cancer gene therapy: Recent advances, challenges, and strategies.
    Wang K; Kievit FM; Zhang M
    Pharmacol Res; 2016 Dec; 114():56-66. PubMed ID: 27771464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Rescue of nonsense mutated p53 by readthrough leads to apoptosis in cancers cells].
    Floquet C; Rousset JP; Bidou L
    Med Sci (Paris); 2011; 27(6-7):585-6. PubMed ID: 21718640
    [No Abstract]   [Full Text] [Related]  

  • 45. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular targets and cancer therapeutics: discovery, biology, and clinical applications. October 29-November 2, 2001. Miami Beach, Florida, USA. Abstracts.
    Clin Cancer Res; 2001 Nov; 7 Suppl():3653s-3852s. PubMed ID: 11727717
    [No Abstract]   [Full Text] [Related]  

  • 47. MicroRNAs as Onco-miRs, drivers of cancer.
    Hede K
    J Natl Cancer Inst; 2010 Sep; 102(17):1306-8. PubMed ID: 20739651
    [No Abstract]   [Full Text] [Related]  

  • 48. [Gene therapy applications in gynecologic malignances management].
    Gromadzka A; Kubiczak M; Jankowska A
    Ginekol Pol; 2010 Jan; 81(1):50-4. PubMed ID: 20232700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The CINSARC signature: prognostic and predictive of response to chemotherapy?
    Bertucci F; Finetti P; Sabatier R; Birnbaum D
    Cell Cycle; 2010 Oct; 9(19):4025-7. PubMed ID: 20978372
    [No Abstract]   [Full Text] [Related]  

  • 50. Survivin-Based Treatment Strategies for Squamous Cell Carcinoma.
    Santarelli A; Mascitti M; Lo Russo L; Sartini D; Troiano G; Emanuelli M; Lo Muzio L
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. K(+) channels as therapeutic targets in oncology.
    Stühmer W; Pardo LA
    Future Med Chem; 2010 May; 2(5):745-55. PubMed ID: 21426201
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Gene expression profiles in the diagnosis and prognosis of cancer].
    Kopper L; Tímár J
    Magy Onkol; 2002; 46(1):3-9. PubMed ID: 12050676
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The promising alliance of anti-cancer electrochemotherapy with immunotherapy.
    Calvet CY; Mir LM
    Cancer Metastasis Rev; 2016 Jun; 35(2):165-77. PubMed ID: 26993326
    [TBL] [Abstract][Full Text] [Related]  

  • 54. At a crossroads in oncology.
    Kamb A
    Curr Opin Pharmacol; 2010 Aug; 10(4):356-61. PubMed ID: 20542731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. MicroRNA-34a: A Versatile Regulator of Myriads of Targets in Different Cancers.
    Farooqi AA; Tabassum S; Ahmad A
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29036883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. K-ras as a target for cancer therapy.
    Friday BB; Adjei AA
    Biochim Biophys Acta; 2005 Nov; 1756(2):127-44. PubMed ID: 16139957
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Encapsulation of nucleic acids and opportunities for cancer treatment.
    Brannon-Peppas L; Ghosn B; Roy K; Cornetta K
    Pharm Res; 2007 Apr; 24(4):618-27. PubMed ID: 17372693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.
    Talbot DC; Ranson M; Davies J; Lahn M; Callies S; André V; Kadam S; Burgess M; Slapak C; Olsen AL; McHugh PJ; de Bono JS; Matthews J; Saleem A; Price P
    Clin Cancer Res; 2010 Dec; 16(24):6150-8. PubMed ID: 21041181
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circular RNAs: a new frontier for cancer diagnosis and therapy.
    Zhang M; Xin Y
    J Hematol Oncol; 2018 Feb; 11(1):21. PubMed ID: 29433541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New approaches in cancer treatment.
    Sikic BI
    Ann Oncol; 1999; 10 Suppl 6():149-53. PubMed ID: 10676567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.